Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. (2020)
Attributed to:
Integrating innovative technologies for genotyping and phenotyping in stratified medicine
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers12051278
PubMed Identifier: 32443649
Publication URI: http://europepmc.org/abstract/MED/32443649
Type: Journal Article/Review
Volume: 12
Parent Publication: Cancers
Issue: 5
ISSN: 2072-6694